Targeted price and payment reforms can reduce healthcare costs without reducing access or quality

What's this about?

People disagree about whether health care price and pay changes can cut costs without harming care or access.

The answer depends on how leaders build, check, and fix these changes.

What supporters say

• Paying care teams for good results, not each task, can bring small savings while keeping care safe.
• One price for all payers and set hospital budgets can slow hospital spending.
• Public talks with drug firms may lower prices without blocking patients from needed drugs.

What critics say

• Adding more people to health plans often raises spending at first.
• Broad fees for patients can make people skip both needed and less-needed care.

How to read this

The number of points on each side does not show who is right; strong proof matters more.

The bottom line

These changes can lower costs without clearly hurting care or access, but they do not always work.

The best results need checks for fair care, safe results, sick patients, and equal access; some savings claims remain unsure.

Targeted changes to healthcare prices and payment incentives can lower spending without necessarily reducing access or quality, but the evidence supports a conditional conclusion rather than a guarantee. Success depends on careful design, monitoring and protections against unequal effects.

The case for

The strongest support comes from payment reforms that move away from unlimited fee-for-service billing. Medicare accountable care organizations, which give provider groups incentives to manage patients’ overall care, have produced savings in some cases while maintaining or improving selected quality measures. The average savings have been modest and uneven, however, varying with the group’s experience, the way targets are set and its ability to manage care. 1 (see Figure 1)

These results suggest that savings are more credible when providers remain responsible for patient outcomes. Risk adjustment, audits and quality measures can help prevent reforms from rewarding providers simply for spending less, avoiding sicker patients or reducing needed services.

Hospital payment changes offer another possible route. Maryland’s all-payer system and global budgets limit the growth of hospital spending across insurers and give hospitals less reason to increase revenue by providing more services. The Maryland experience suggests that such rules can support care coordination and reduce volume-based incentives, although the available evidence does not prove that the model will produce the same results everywhere. 3

Drug-price negotiation takes a different approach: it seeks lower prices for selected high-cost medicines without making patients ineligible for treatment. Analyses of Medicare negotiations project meaningful discounts for some products, supporting the possibility of savings without directly rationing clinical care. But projected discounts are not the same as confirmed, long-term savings, and the effects on availability, new medicines and research remain uncertain. 2

The case against

The main warning is that lower spending does not automatically mean better policy. The RAND health-insurance experiment found that deductibles and coinsurance reduced both healthcare use and spending, but patients cut back on beneficial care as well as unnecessary care. Lower-income participants experienced worse outcomes in some areas. Broad cost sharing can therefore reduce care indiscriminately, rather than targeting waste or excessive prices. 4 (see Figure 2)

Coverage expansion points to a different limitation. In Oregon’s randomized Medicaid experiment, gaining coverage increased healthcare use and protected people financially. Several measured health outcomes did not improve significantly during the first year, meaning that expanding coverage should not be treated as an immediate way to reduce total spending. 5

Even reforms aimed at providers can cause harm if they are not closely watched. Reviews of prospective payment systems have found possible efficiency gains, but also coding changes, reduced service intensity, patient selection and quality declines when oversight is weak. A payment system designed to reward lower spending can begin to resemble a blunt cut if providers respond by avoiding costly patients or limiting needed care.

The evidence also has important limits. Studies measure different things—spending, use, access, quality, equity and results over different time periods—so their findings cannot be compared directly. The ACO evidence shows modest and variable average effects, Maryland research is largely focused on implementation, and drug-negotiation savings are mostly modeled rather than observed. Conflicts of interest and differences in how studies classify them add further uncertainty.

The bottom line

The evidence favors the claim, but only in a qualified way. Targeted payment and price reforms appear capable of producing savings while preserving some access and quality measures. The strongest support is for conditional feasibility, not for a universal or lasting guarantee that all three goals will improve together.

There is greater confidence that blunt cost sharing and unmonitored payment cuts are unsafe substitutes for targeted reform. Confidence is lower that any particular policy will protect access, quality and equity across all populations and over time. Selective drug negotiation and payment reforms are most defensible when they include monitoring for shortages, underservice, patient selection, access losses and longer-term effects on innovation. The central unanswered question is whether those safeguards can continue to work when reforms expand beyond the settings in which they were studied.